Changes in quality of life following hypoglycaemia in adults with type 2 diabetes: A systematic review of longitudinal studies by Matlock, K.A. et al.
This is a repository copy of Changes in quality of life following hypoglycaemia in adults 
with type 2 diabetes: A systematic review of longitudinal studies.




Matlock, K.A., Broadley, M., Hendrieckx, C. et al. (7 more authors) (2021) Changes in 
quality of life following hypoglycaemia in adults with type 2 diabetes: A systematic review 





This article is distributed under the terms of the Creative Commons Attribution-NonCommercial (CC BY-NC) 
licence. This licence allows you to remix, tweak, and build upon this work non-commercially, and any new 
works must also acknowledge the authors and be non-commercial. You don’t have to license any derivative 
works on the same terms. More information and the full terms of the licence here: 
https://creativecommons.org/licenses/ 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
Diabetic Medicine. 2021;00:e14706.    | 1 of 18
https://doi.org/10.1111/dme.14706
wileyonlinelibrary.com/journal/dme
Received: 13 July 2021 | Accepted: 28 September 2021
DOI: 10.1111/dme.14706  
S Y S T E M A T I C  R E V I E W
Changes in quality of life following hypoglycaemia in adults 
with type 2 diabetes: A systematic review of longitudinal 
studies
Kevin A. Matlock1  |   Melanie Broadley1  |   Christel Hendrieckx2  |    
Mark Clowes3  |   Anthea Sutton3  |   Simon R. Heller4,5  |    
Bastiaan E. de Galan6,7,8  |   Frans Pouwer1,9  |   Jane Speight2  |    
for the Hypo- RESOLVE consortium
This is an open access article under the terms of the Creat ive Commo ns Attri butio n NonCo mmercial License, which permits use, distribution and reproduction in any 
medium, provided the original work is properly cited and is not used for commercial purposes.
© 2021 The Authors. Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK.
1Psychology Department, University of 
Southern Denmark, Odense, Denmark
2Australian Centre for Behavioural 
Research in Diabetes, Melbourne, 
Victoria, Australia
3School of Health and Related 
Research, University of Sheffield, 
Sheffield, UK
4Sheffield Teaching Hospitals 
Foundation Trust, Sheffield, UK
5Department of Oncology and 
Metabolism, University of Sheffield, 
Sheffield, UK
6Department of Internal Medicine, 
Radboud University Nijmegen Medical 
Centre, Nijmegen, The Netherlands
7Division of Endocrinology, 
Department of Internal Medicine, 
Maastricht University Medical Centre, 
Maastricht, The Netherlands
8CARIM School for Cardiovascular 
Diseases, Maastricht University, 
Maastricht, The Netherlands
9Steno Diabetes Center, Odense, 
Denmark
Correspondence
Kevin A. Matlock, Psychology 




This study was funded by the EU 
Innovative Medicines Initiative 2 
Abstract
Aim: To conduct a systematic review of published studies reporting on the lon-
gitudinal impacts of hypoglycaemia on quality of life (QoL) in adults with type 2 
diabetes.
Method: Database searches with no restrictions by language or date were con-
ducted in MEDLINE, Cochrane Library, CINAHL and PsycINFO. Studies were 
included for review if they used a longitudinal design (e.g. cohort studies, ran-
domised controlled trials) and reported on the association between hypoglycae-
mia and changes over time in patient- reported outcomes related to QoL.
Results: In all, 20 longitudinal studies published between 1998 and 2020, repre-
senting 50,429 adults with type 2 diabetes, were selected for review. A descrip-
tive synthesis following Synthesis Without Meta- analysis guidelines indicated 
that self- treated symptomatic hypoglycaemia was followed by impairments in 
daily functioning along with elevated symptoms of generalised anxiety, diabetes 
distress and fear of hypoglycaemia. Severe hypoglycaemic events were associ-
ated with reduced confidence in diabetes self- management and lower ratings of 
perceived health over time. Frequent hypoglycaemia was followed by reduced 
energy levels and diminished emotional well- being. There was insufficient evi-
dence, however, to conclude that hypoglycaemia impacted sleep quality, depres-
sive symptoms, general mood, social support or overall diabetes- specific QoL.
Conclusions: Longitudinal evidence in this review suggests hypoglycaemia is 
a common occurrence among adults with type 2 diabetes that impacts key fac-
ets in the physical and psychological domains of QoL. Nonetheless, additional 
longitudinal research is needed— in particular, studies targeting diverse forms 
of hypoglycaemia, more varied facets of QoL and outcomes assessed using 
hypoglycaemia- specific measures.
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1  |  INTRODUCTION
For adults with type 2 diabetes, hypoglycaemia is a common 
side effect of glucose- lowering medication. An estimated 
83% of insulin and 59% of sulfonylurea users experience 
symptoms of hypoglycaemia annually.1 Hypoglycaemia 
can be distressing2 and may interfere with diabetes self- 
management, resulting in greater glucose variability and 
suboptimal HbA1c.
3 Hypoglycaemia is also associated with 
heightened risks for long- term neurological and cardiovas-
cular complications,4 and poorer quality of life (QoL).5
Disagreements remain regarding the suitability of 
specific instruments,6 but most agree QoL is best con-
ceptualised as a subjective appraisal spanning multiple 
dimensions of life, particularly facets in the physical, psy-
chological and social domains.7 Hypoglycaemia has been 
linked primarily to detriments in the physical domain, in-
cluding diminished work capacity and sleep quality,8 and 
the psychological domain, including elevated anxiety9 and 
depression10 symptoms.
Previous systematic reviews reinforce these findings 
but present two major limitations. First, evidence linking 
hypoglycaemia and QoL comes predominantly from cross- 
sectional studies.11,12 The lack of longitudinal research 
makes it difficult to determine whether hypoglycaemia 
impacts QoL or merely shares an independent association. 
Second, outcomes in longitudinal studies have typically 
been assessed using a handful of domain- specific mea-
sures which fall short of capturing the full breadth of QoL 
(e.g. a single mood questionnaire). In fact, no systematic 
review to date has investigated the longitudinal impacts of 
hypoglycaemia on multiple facets of QoL; a single review 
from 2010 examined longitudinal data from randomised 
controlled trials (RCTs) but targeted measures related ex-
clusively to emotional well- being— a single facet of psy-
chological QoL— and health status.13
This systematic review aimed to summarise evidence 
from longitudinal studies reporting on the association be-
tween hypoglycaemia and changes in QoL among adults 
with type 2 diabetes. QoL was characterised using a wide 
scope, with measures considered for inclusion if they were 
subjective evaluations of (a) generic QoL; (b) facets in the 
physical, psychological or social domains of generic QoL; 
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Novelty statement
What is already known?
● Cross- sectional studies report negative associa-
tions between hypoglycaemia and numerous 
facets of quality of life, but systematic reviews of 
longitudinal evidence have focused exclusively 
on health status and emotional well- being.
What has the study found?
● Severe hypoglycaemia is associated with re-
duced diabetes self- efficacy and perceived 
health.
● Self- treated hypoglycaemia is followed by im-
paired daily functioning and elevated symp-
toms of anxiety, diabetes distress and fear of 
hypoglycaemia.
● Frequent hypoglycaemia is followed by dimin-
ished energy and emotional well- being.
What are the implications of the study?
● Understanding which specific facets of quality 
of life are impacted by hypoglycaemia may en-
able targeted interventions to improve quality 
of life on an outcome- by- outcome basis.
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or (c) diabetes- specific or hypoglycaemia- specific QoL 
(and constituent domains).
2  |  METHOD
This systematic review was conducted in accordance with 
Preferred Reporting Items for Systematic Reviews and 
Meta- Analyses (PRISMA) guidelines.14 The protocol is 
registered on Prospective Register of Systematic Reviews 
(PROPSERO) under record no. CRD42020154023.
2.1 | Search strategy
A database search strategy was developed to identify pub-
lished studies reporting on the relationship between hypo-
glycaemia and patient- reported outcomes (PROs) related 
to QoL (Table S1). This approach employed a comprehen-
sive set of search terms in four categories: population (e.g. 
‘type 2 diabetes’), exposure (e.g. ‘hypoglycaemia’), generic 
and specific outcomes (e.g. ‘quality of life’, ‘well- being’) 
and study design (e.g. ‘randomised controlled trial’, ‘co-
hort study’). No restrictions were placed on language or 
date of publication. Searches of MEDLINE, Cochrane 
Library, CINAHL and PsycINFO were completed on 5 
November 2020.
2.2 | Screening process
Studies were eligible for inclusion if they (a) sampled 
adults (18+ years old) with type 2 diabetes; (b) had a lon-
gitudinal quantitative design; (c) assessed the occurrence 
of hypoglycaemia; (d) included PRO(s) related to generic, 
diabetes- specific or hypoglycaemia- specific QoL; and (e) 
reported on the statistical relationship between hypogly-
caemia and changes in PROs over time. Mixed- population 
studies (e.g. combined samples of adults with type 1 and 
type 2 diabetes) were eligible for inclusion if results for 
adults with type 2 diabetes were reported separately. 
Outcomes were restricted to standardised PROs to main-
tain a person- centred, subjective appraisal of QoL and to 
maximise validity and reliability of findings, reducing het-
erogeneity and enabling comparisons across studies.
Records identified through database searches were 
split between five assessors (AC, AS, KM, MB and MC) 
who screened titles and abstracts; 15% were double- 
screened to ensure consistent application of inclusion 
criteria. Short- listed records were full text screened in-
dependently by two reviewers (KM and MVJ) as dual 
screening produces fewer errors than single screening.15 
Studies meeting inclusion criteria were subjected to 
forward citation searches on Web of Science and back-
ward citation searches. To address publishing and da-
tabase indexing bias, hand searches were conducted on 
ClinicalTrials.gov and references from excluded studies 
deemed to be of interest. As an additional safeguard, 10% 
of excluded records, chosen at random, were double- 
screened by a third reviewer (MCJC). Inconsistencies 
were discussed between reviewers until consensus was 
reached.
2.3 | Study quality
Quality of included studies was rated by a reviewer (KM) 
using critical appraisal tools from the Joanna Briggs 
Institute (JBI) specific to RCTs and cohort studies,16 and 
ratings were checked by a second reviewer (MVJ). To pro-
vide a concise metric for quantitative comparisons across 
designs, an overall quality proportion (αq) was calculated 
for each study using a count score17 whereby the number 
of ‘yes’ items was divided by the total number of items on 
the appraisal tool (‘unclear’ items were counted as half, 
while ‘not applicable’ items were excluded). Proportions 
ranged from 0 to 1 and were interpreted in a manner simi-
lar to Cronbach's α18: αq ≥ 0.9 (excellent), αq ≥ 0.8 (good), 
αq ≥ 0.7 (acceptable) and αq < 0.7 (poor).
2.4 | Extraction and synthesis
One reviewer (KM) extracted data pertaining to study 
authors, publication year, country, sample size, study 
design, intervention type, hypoglycaemia measures and 
frequency, PROs related to QoL, and findings regarding 
the relationship between hypoglycaemia and changes in 
PROs. Extractions for measures and results were verified 
independently by another reviewer (MVJ) and disagree-
ments were resolved by consensus. Due to the diversity 
of PROs and inconsistent reporting of statistical values, 
meta- analysis and subgroup analysis were not possible. 
Consequently, following Synthesis Without Meta- analysis 
(SWiM) guidelines,19 descriptive synthesis of hypoglycae-
mic impacts was performed with PROs grouped by QoL 
domain7 and specificity to better demarcate the degree of 
generalisability.
3  |  RESULTS
3.1 | Study selection and characteristics
Database searches identified 12,571 records. Abstract 
and title screening excluded 12,096 records, and full- text 
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screening eliminated 460 records, leaving 15 studies20– 34 
that satisfied inclusion criteria. Backward and forward 
citation searches of these studies identified 3 additional 
studies,35– 37 and hand searches identified 2 studies,38,39 re-
sulting in 20 total studies selected for extraction and syn-
thesis (Figure 1).
These 20  studies, published between 1998 and 2020, 
sampled adults with type 2 diabetes (N  =  50,429) from 
more than 20 countries (Table 1). Studies were conducted 
in Europe (n = 9), North America (n = 5), Asia (n = 3) 
and other regions worldwide (n  =  3). Participants were 
generally older adults, with a mean age of 60 across stud-
ies (range: 55– 71). Gender ratios varied greatly between 
studies (range: 32%– 74% female), but overall represen-
tation was roughly balanced (M  =  45% female). Studies 
used either cohort (60%) or RCT (40%) designs, and most 
examined the effectiveness of oral or injectable glucose- 
lowering medications (n  =  10) or self- management 
interventions (n = 6). The remainder had no stated inter-
vention (n = 4).
3.2 | Study quality
Quality proportions (Table  1) revealed that study qual-
ity was excellent (n = 9) or good (n = 3) for cohort stud-
ies (0.80 ≤ αq ≤ 1.00). Quality was more diverse for RCTs 
(0.58 ≤ αq ≤ 0.88), with studies rating as good (n = 3), ac-
ceptable (n = 3), or poor (n = 2). Apart from two stud-
ies,29,35 however, quality was acceptable or better for both 
cohort studies (Mαq = 0.92) and RCTs (Mαq = 0.75), and 
differences in quality were largely attributable to omis-
sions in reporting as few RCTs provided information 
about blinding (20%) or reliability statistics for measures 
(25%). These criteria were deemed less relevant as hypo-
glycaemia was not a component of study interventions, 
F I G U R E  1  PRISMA flow diagram of 
the search and screening process
 















T A B L E  1  Characteristics and findings of included studies






Quality of life assessment
Impact of self- 
treated symptomatic 
hypoglycaemia
Measure Outcome Directiona Sig.
Ali et al. (2012) 35 RCT US 2053 Intensive versus standard 
glucose control
0.58 SF- 36 General health
Physical health NS
Mental health NS
Briggs et al. (2017) 20 RCT Worldwide 16,492 Saxagliptin versus placebo 0.77 EQ- 5D General health b <0.05
de Sonnaville et al. 
(1998)
36 Cohort Netherlands 237 Insulin versus oral 
medication
1.00 POMS Negative mood c NS
Genovese et al. 
(2013)
21 Cohort Italy 1046 Vildagliptin + metformin 0.90 WPAI Work/school impairment
Activity impairment 0.001
Goddijn et al. 
(1999)
22 Cohort Netherlands 99 Insulin versus oral 
medication
1.00 RAND- 36 General health
Mental health NR
Haluzik et al. 
(2018)
23 Cohort Eastern Europe 6369 None 0.93 Targeted 
question
Work impairment NA
Jódar et al. (2020) 24 RCT Worldwide 3297 Semaglutide versus placebo 0.77 SF- 36 General health
Physical health <0.01
Mental health 0.08
Malanda et al. 
(2011)
25 Cohort UK 453 G- Meter versus standard 
monitoring
1.00 EQ- 5D General health 0.23




IPQ- R Illness perceptions
Illness control NS
Emotional distress 0.24
Menard et al. (2007) 26 RCT Canada 72 Intensive versus standard care 0.88 DQOL DQOL NS
Mitchell et al. 
(2013)
27 Cohort UK 1329 None 0.85 HFS- II Fear of hypoglycaemia d <0.001
Nauck et al. (2019) 28 RCT Worldwide 3014 Liraglutide versus placebo 0.85 EQ- 5D General health b <0.001
EQ- VAS General health b 0.98
(Continues)
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Quality of life assessment
Impact of self- 
treated symptomatic 
hypoglycaemia
Measure Outcome Directiona Sig.
Nicolucci et al. 
(2011)
29 RCT Italy 238 Telephone versus standard 
care





SF- 36 General health
Physical health NS
Mental health 0.004
Pathan et al. (2018) 38 Cohort Southeast Asia 2594 None 0.93 Targeted 
question
Work impairment NA
Peyrot et al. (2008) 30 RCT US 211 Pramlintide versus placebo 0.85 DDS Diabetes distress NS
Pichayapinyo et al. 
(2018)
31 Cohort Thailand 35 Telephone assistance 0.85 DDS Diabetes distress NS
SEDS Diabetes self- efficacy NS
PHQ- 8 Depressive symptoms NS
SSQ Social support NS
PROMIS General health
Sleep disturbance NS
Polonsky et al. 
(2018)
39 Cohort US 424 None 0.90 WHO- 5 Emotional well- being NS
GAD Anxiety symptoms <0.01
PHQ- 8 Depressive symptoms NS
DDS Diabetes distress <0.05




Ritter et al. (2016) 37 RCT US 1674 Efficacy care versus placebo 0.77 DSES Diabetes self- efficacy 0.026
Torre et al. (2018) 32 Cohort Portugal 1303 DPP- 4 versus GLP- 1 vs.SGLT2 0.90 EQ- 5D General health NS
EQ- VAS General health NS
T A B L E  1  (Continued)
 
 





















Quality of life assessment
Impact of self- 
treated symptomatic 
hypoglycaemia
Measure Outcome Directiona Sig.
Wieringa et al. 
(2018)
33 Cohort Netherlands 911 Insulin glargine 1.00 WHO- 5 Emotional well- being c 0.30




Yang et al. (2014) 34 Cohort China 8578 Biphasic insulin aspart 30/70 0.80 EQ- VAS General health b <0.001
Abbreviations: DDS, Diabetes Distress Scale; DQOL, Diabetes Quality of Life measure; DSES, Diabetes Self- Efficacy Scale; EQ- 5D, EuroQol 5- Dimension health status instrument; EQ- VAS, EuroQol Visual Analogue 
Scale; GAD, General Anxiety Disorder scale; HFS- II, Hypoglycaemia Fear Survey version II; IPQ- R, Illness Perception Questionnaire Revised; NA, not applicable; NR, not reported; NS, not significant (no p- value 
reported); PHQ- 8, Patient Health Questionnaire 8- item; POMS, Profile of Mood States; PROMIS, Patient- Reported Outcomes Measurement Information System; RAND- 36, RAND Corporation 36- item health survey; 
RCT, randomised controlled trial; SEDS, Self- Efficacy for Diabetes Scale; SF- 36, Medical Outcomes Study Short Form 36- item health survey; SSQ, Social Support Questionnaire; W- BQ12 and W- BQ22, Well- Being 
Questionnaire 12- item and 22- item; WHO- 5, World Health Organisation 5- item well- being index; WPAI, Work Productivity and Activity Impairment.
aIncreases and decreases in outcomes are depicted with upward ( ) and downward arrows ( ), respectively; associations of unknown direction are depicted with a dash ( ); black and grey symbols indicate 
significant and non- significant or untested effects, respectively.
bReflects impact of severe hypoglycaemic events only.
cDirection and significance of impact was similar for severe hypoglycaemic events.
dReflects impact of any hypoglycaemic event.
eDirection of impact for severe hypoglycaemic events was similar but not significant, p = 0.23
TABLE 1 (Continued)
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and thus was unaffected by blinding, and nearly all stud-
ies relied on PROs with established validity and reliability. 
Consequently, included studies were interpreted as hav-
ing good quality given the quasi- experimental nature of 
the variables under review (see Tables S2 and S3 for item- 
by- item appraisals).
Regarding hypoglycaemic impacts on QoL, evidence 
across studies was limited by the narrow scope of QoL 
instruments and the lack of hypoglycaemia- specific mea-
sures. Furthermore, only three studies explicitly con-
trolled for the intervention25,28,29 and none controlled for 
diabetes education. Reporting of statistical values also var-
ied widely, with most studies lacking standardised effect 
sizes and other values necessary for clear interpretation 
and meta- analysis.
3.3 | Frequency and severity of 
hypoglycaemia
All studies assessed hypoglycaemia using self report, ex-
cept for one RCT that used clinical records.20 Recall pe-
riods for hypoglycaemia ranged from 1 to 36  months, 
though recall in most studies (70%) was 6  months or 
longer. Reporting on hypoglycaemic severity was absent in 
four studies.21,24,29,37 Remaining studies described the se-
verity of hypoglycaemia using classifications comparable 
to those given by Malanda et al.25: Grade 1, asymptomatic 
episodes accompanied by glucose measurements below 
4.0 mmol/L (72 mg/dl); Grade 2, self- treated symptomatic 
episodes; Grade 3, severe events requiring assistance; and 
Grade 4, severe events requiring hospitalisation.
Nearly, all studies (90%) reported on the occurrence of 
hypoglycaemia during the study period (Table 2). A few 
studies provided episode frequencies, but most (75%) cate-
gorised participants based on whether or not they had ex-
perienced hypoglycaemia. In studies where asymptomatic 
and symptomatic episodes were considered together, hy-
poglycaemia was common, affecting 28%– 54% of partici-
pants over a 1- month period.23,27 Symptomatic self- treated 
and severe hypoglycaemia were less common. Over a 2- 
year period, studies reported 23%– 86% of participants ex-
perienced at least one self- treated episode32,39 and 1%– 23% 
experienced at least one severe event.32,39
3.4 | Impact of hypoglycaemia on 
generic QoL
Studies examined hypoglycaemic impacts using 11 PROs 
related to generic QoL. Relevant PROs almost exclusively 
targeted facets within the physical and psychological 
domains. Impacts on each PRO are summarised in Table 1, 
and detailed statistical results are provided in Table 3.
3.4.1 | Health status
The most common outcome, perceived health, was as-
sessed in 45% of studies. Although frequently interpreted 
as a global assessment of generic or health- related QoL, 
PROs assessing health status measured facets exclusively 
in the physical and psychological domains.
The EuroQol 5- Dimension (EQ- 5D) health instrument 
was the most frequently adopted PRO in studies target-
ing health status (n = 5). While the full EQ- 5D includes 
four physical health items and one mental health item, all 
studies save one25 used the EQ- 5D utility index, a summed 
total of all items rated against a normed sample,20,28,32 or 
the EuroQoL Visual Analogue Scale (EQ- VAS), a single 
item rating general health on a scale from 1 to 100.32,34
Three studies focusing on severe events found EQ- 5D 
utility index20,28 and EQ- VAS scores34 were negatively as-
sociated with hypoglycaemia; compared to those report-
ing no events, those experiencing at least one severe event 
had lower ratings of perceived health. In contrast, two co-
hort studies showed that self- treated hypoglycaemia was 
not associated with EQ- 5D totals25 or EQ- VAS scores.27
The Medical Outcomes Study Short Form 36- item 
(SF- 36) survey, a broad health status measure comprised 
of Mental and Physical Component scales, was adopted 
solely by RCTs (n  =  3). A 12- month study examining 
the impact of severe hypoglycaemia revealed no signifi-
cant declines in either physical or mental health among 
those experiencing severe events.35 Two studies which 
did not specify hypoglycaemic severity likewise reported 
no decline in physical health among those experiencing 
hypoglycaemia over a 1- month29 or 26- month24 period. 
One of these studies did find that treatment- related im-
provements in mental health were blunted among those 
experiencing three or more hypoglycaemic episodes,29 
but the other reported no change in Mental Component 
scores.24 Moreover, the latter was consistent with a study 
examining mental health using a subscale of the RAND 
Corporation 36- item (RAND- 36) survey— a measure that 
parallels the SF- 36— which found no change in mental 
health following self- treated hypoglycaemia.22
Taken as a whole, findings from health status stud-
ies (n  =  9) indicated perceptions of health worsened 
among those experiencing hypoglycaemic over a period 
of 6– 36 months, but only for events severe enough to re-
quire assistance. Furthermore, this impact was only evi-
dent when health status was assessed using the EQ- 5D. 
Findings regarding self- treated hypoglycaemia were less 
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T A B L E  2  Hypoglycaemic episodes reported in included studies
Authors (year) Reference
Measure characteristics





Ali et al. (2012) 35 Yes/no 12 Grade 3 2.8% reported 1+ episodes
Briggs et al. (2017) 20 Yes/no 12 Grade 4 0.5% hospitalised for 1+ events
de Sonnaville et al. (1998) 36 Frequency 1 Grade 3 4.4 events per person- year
Genovese et al. (2013) 21 Frequency 12 NR NR
Goddijn et al. (1999) 22 Yes/no 1 Grade 2 6.4% and 19.1% reported 1+ 
episodes (at baseline and 
1 year, respectively)
Haluzik et al. (2018) 23 Yes/no 1 Grades 1– 2 57.0% and 53.7% reported 1+ 
episodes (at baseline and 
1 month, respectively)
Grade 3 6.7% and 7.6% reported 1+ events 
(at baseline and 1 month, 
respectively)
Jódar et al. (2020) 24 Yes/no 26 NR 22.1% reported 1+ episodes
Malanda et al. (2011) 25 Yes/no 12 Grade 1 25.2% reported 1+ episodes
Grade 2 17.7% reported 1+ episodes
Menard et al. (2007) 26 Yes//no 12 Grade 2 20.8% reported 1+ episodes
Frequency Grade 2 21.6 episodes per person- year
Mitchell et al. (2013) 27 Yes/no 1 Grades 1– 3 27.5% reported 1+ episodes
Nauck et al. (2019) 28 Yes/no 36 Grade 3 42.3% reported 1+ events
Nicolucci et al. (2011) 29 Frequency 1 NR 7.2, 19.2 and 21.6 episodes per 
person- year (at 1, 5 and 
6 months, respectively)
Pathan et al. (2018) 38 Yes/no 1 Grade 2– 3 40.6% and 97.3.1% reported 1+ 
episodes (at baseline and 
1 month, respectively)
Grade 3 52.2% and 76.9% reported 1+ 
events (at baselineb and 
1 month, respectively)
Frequency Grade 2– 3 12.2 and 22.6 episodes per 
person- year (at baseline and 
1 month, respectively)
Grade 3 2.2 and 12.2 events per person- 
year (at baselineb and 
1 month, respectively)
Peyrot et al. (2008) 30 Frequency 16 Grade 2 2.3 episodes per person- year
Pichayapinyo et al. (2019) 31 Severity 3 Grade 2 NR
Polonsky et al. (2018) 39 Yes/no 24 Grade 2 86% reported 1+ episodes
Grade 3 41% reported 1+ events
Ritter et al. (2016) 37 Symptom severity 6 NR NR
Torre et al. (2019) 32 Yes/no 26 Grade 2– 3 22.8% reported 1+ episodes
Grade 3 <1% reported 1+ events
(Continues)
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clear, with EQ- 5D studies reporting no impact, and SF- 
36 studies reporting mixed results for mental health.
3.4.2 | Facets in the physical domain of QoL
Energy and sleep
Two glucose monitoring studies examined energy level 
using the Energy subscale of the Well- Being Questionnaire 
(W- BQ), with one reporting no change in energy among 
those experiencing one or more asymptomatic or self- 
treated symptomatic hypoglycaemic episodes over a 
12- month period,25 and the other reporting a decline in 
energy following four or more episodes of unspecified 
severity within 30 days.29 A small- sample study31 exam-
ined sleep quality using a subscale of the Patient- Reported 
Outcomes Measurement Information System (PROMIS), 
revealing a weak, non- significant correlation between 
more frequent symptoms of hypoglycaemia and greater 
sleep disturbance (see Table 3 for effect sizes).
Everyday functioning
Two studies assessed impairment in the workplace among 
participants from Eastern Europe23 and Southeast Asia.38 
Over a 30- day period, approximately 3% of adults with 
type 2 diabetes reported having been absent from work, 
and 2%– 5% reported having left work early, as a direct 
consequence of hypoglycaemia. Impairment during 
non- work activities (e.g. shopping) was examined in one 
study using the Activity Impairment subscale of the Work 
Productivity and Activity Impairment questionnaire,21 
revealing that an increase in the frequency of hypogly-
caemia over a 12- month period was followed by greater 
impairments in everyday functioning than those who ex-
perienced no change or a decrease.
3.4.3 | Facets in the psychological domain  
of QoL
Mood
The most commonly assessed facet within the psychologi-
cal domain of QoL, mood, was examined in 25% of studies. 
Three studies investigated general mood using the Profile 
of Mood States survey36 or the Positive and Negative Mood 
subscales of the 12- item25 and 22- item29 W- BQ. These 
studies provided no evidence for an association between 
hypoglycaemia and general mood, regardless of mood 
valence (i.e. positivity or negativity) or hypoglycaemic 
severity.
Symptoms of mood disorders were examined in three 
studies. One study using the broad Anxiety subscale of 
the 22- item W- BQ found that those experiencing one, two 
or three hypoglycaemic episodes (but not four or more) 
reported reduced anxiety.29 However, a study using the 
narrower General Anxiety Disorder scale reported that 
those who experienced at least one self- treated hypogly-
caemic episode in 24 months developed elevated anxiety 
symptoms.39 Three studies assessed depressive symptoms 
using either the 8- item Patient Health Questionnaire31,39 
Authors (year) Reference
Measure characteristics





Wieringa et al. (2018) 33 Yes/no 3 Grade 2– 3 37.2%, 42.5% and 43.5% reported 
1+ episodes (at baseline, 3 
and 6 months, respectively)
Grade 3 3.1%, 4.3% and 5.6% reported 
1+ events (at baseline, 3 and 
6 months, respectively)
Yang et al. (2014) 34 Frequency 6 Grade 2 2.17 and 1.54 episodes per 
person- year (at baseline and 
6 months, respectively)
Grade 3 0.15 and 0.0 events per person- 
year (at baseline and 
6 months, respectively)
Note: Grade 1, asymptomatic hypoglycaemia; Grade 2, self- treated symptomatic hypoglycaemia; Grade 3; severe hypoglycaemia requiring assistance; Grade 4, 
severe hypoglycaemia requiring hospitalisation.
Abbreviation: NR, not reported.
aUnless otherwise stated, values reflect occurrence of hypoglycaemia during the study period. Occurrence of hypoglycaemia at baseline is presented when 
reported by the study.
bRecall period was 6 months for baseline occurrence of severe (Grade 3) hypoglycaemic events.
T A B L E  2  (Continued)
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T A B L E  3  Relative size of impact of hypoglycaemia in included studies
Authors (year)a Reference Analysis Quantified impact on measures of quality of life
Ali et al. (2012) 35 Linear regression No; 1+ severe hypoglycaemic events did not lead to changes in 
mental or physical health; compared to those reporting no 
events, those reporting severe events experienced a decline 
in SF- 36 Mental Component scores, B = – 2.14, and a rise in 
SF- 36 Physical Component scores, B = 1.05, though none 
of these impacts were significant, ps > 0.05
Briggs et al. 
(2017)
20 Linear regression Yes; 1+ severe hypoglycaemic events led to a decrease 
in general health; following hospitalisation for 
hypoglycaemia, EQ- 5D Utility Index scores dropped 
(MΔ = – 0.019, SEΔ = 0.024), p < 0.05
Haluzik et al. 
(2018)
23 NA (targeted question) Yes; 1+ hypoglycaemic episodes impaired attendance at 
school or work; during the 1- month study period, 2.5% 
of participants reported taking leave from school or 
work (M = 2.8 days), 2.7% reported arriving late and 
4.9% reported leaving early as a direct consequence of 
hypoglycaemia
Jódar et al. (2020) 24 Linear regression Mixed; 1+ hypoglycaemic episodes (of unspecified severity) 
led to larger improvements in physical health, but not 
mental health, following intervention; change in SF- 36 
Physical Component scores was larger and more positive 
for those reporting hypoglycaemic episodes (MΔ = 1.04, 
SEΔ = 2.4) compared to those reporting no episodes 
(MΔ = 0.5, SEΔ = 0.2), p < 0.01, while change in SF- 
36 Mental Component scores did not differ between those 
reporting episodes (MΔ = – 0.5, SEΔ = 0.4) and those who 
did not (MΔ = 0.3, SEΔ = 0.2), p = 0.08
Malanda et al. 
(2011)
25 ANCOVA (adjusted for gender, 
age, education, diabetes 
duration, intervention)
Mixed; 1+ asymptomatic hypoglycaemic episodes led to 
increased perceived control over diabetes; pairwise 
comparisons showed changes in IPQ- R Control subscale 
scores were larger and more positive for those reporting 
only asymptomatic episodes (MΔ = 1.04, SDΔ = 2.4), 
compared to those reporting self- treated symptomatic 
episodes (MΔ = – 0.3, SDΔ = 2.7), p = 0.007, d = 0.54, 
or no episodes (MΔ = – 0.09, SDΔ = 3.3), p = 0.009, 
d = 0.37. There was no difference between those reporting 
symptomatic or no episodes, p > 0.05. Experiencing 
1+ hypoglycaemic episodes did not affect general 
health, general well- being or diabetes distress; three- 
way comparisons for those reporting no episodes, only 
asymptomatic episodes or self- treated symptomatic 
episodes showed no changes in EQ- 5D (MΔ = – 0.04, 0.01, 
– 0.03, SDΔ = 0.2, 0.2, 0.2), p = 0.23, W- BQ12 (MΔ = – 0.27, 
0.03, 0.16, SDΔ = 5.2, 4.7, 4.0), p = 0.82 or IPQ- R Emotion 
subscale scores (MΔ = 0.39, – 0.27, – 0.79, SDΔ = 3.6, 3.6, 
3.9), p = 0.24
Nauck et al. 
(2019)
28 Linear regression (adjusted 
for gender, region, CVR, 
intervention)
Yes; 1+ severe hypoglycaemic events (requiring assistance or 
confirmed plasma glucose <3.1 mmol/L [56 mg/dl]) led to 
a decrease in general health; compared to those reporting 
no events, those reporting severe events experienced a drop 
in EQ- 5D Utility Index scores (MΔ = – 0.018, SEΔ = 0.004), 
p < 0.001, but no change in VAS scores (MΔ = – 0.009, 
SEΔ = 0.351), p = 0.98
(Continues)
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Authors (year)a Reference Analysis Quantified impact on measures of quality of life
Nicolucci et al. 
(2011)
29 Linear regression (adjusted for 
gender, age, HbA1c, weight, 
intervention)
Yes; 4+ hypoglycaemic episodes (of unspecified severity) led 
to a decrease in general well- being and energy, and smaller 
improvements in mental health following intervention; 
compared to those reporting no episodes, those reporting 
3+ episodes showed a drop in W- BQ22 total, B = – 5.41 
(SE = 1.72), p = 0.002, and W- BQ22 Energy subscale 
scores, B = – 1.45 (SE = 0.49), p = 0.003, and smaller 
improvements in SF- 36 Mental Component scores, 
B = – 5.03 (SE = 1.72), p = 0.004. Those reporting 1– 3 (but 
not 4+) hypoglycaemic episodes showed a drop in W- BQ22 
Anxiety subscale scores, B = – 1.76 (SE = 0.65), p = 0.007
Pathan et al. 
(2018)
38 NA (targeted question) Yes; 1+ hypoglycaemic episodes impaired attendance at 
school or work; during the 1- month study period, 3.2% of 
participants reported taking leave from school or work, 
2.1% reported arriving late and 2.8% reported leaving early 
as a direct consequence of hypoglycaemia
Pichayapinyo 
et al. (2019)
31 Pearson's correlation No; more frequent symptoms of hypoglycaemia did not lead 
to changes in depression, sleep disturbance, social support, 
diabetes distress or diabetes self- efficacy; those reporting 
more symptoms showed a rise in PHQ- 8 total, r = 0.18, and 
PROMIS Sleep Disturbance subscale scores, r = 0.16, as 
well as a drop in SSQ total, r = – 0.12, DDS total, r = – 0.06, 
and SEDS total scores, r = – 0.04, though none of these 
impacts were significant, ps > 0.05
Polonsky et al. 
(2018)
39 ANCOVAb (adjusted for gender, 
age, insulin status)
Mixed; 1+ self- treated symptomatic hypoglycaemic 
episodes led to increased anxiety, diabetes distress and 
hypoglycaemic worry, but no change in depression or 
general well- being; compared to those reporting no 
episodes, those reporting self- treated episodes showed a 
rise in GAD total, β = 0.16, p < 0.01, DDS total, β = 0.12, 
p < 0.05, and HFS- II worry subscale scores, β = 0.18, 
p < 0.01, but no change in PHQ- 8 total, β = 0.09, p > 0.05 
or WHO- 5 total scores, β = 0.02, p > 0.05
Torre et al. (2019) 32 Linear regressionb No; 1+ self- treated hypoglycaemic episodes or severe 
hypoglycaemic events did not lead to minimally important 
changes in general health; following self- treated episodes 
or severe events, there was a non- significant rise in EQ- 
5D utility index, β = 0.29, p = 0.15, and EQ- 5D Visual 
Analogue Scale scores, β = 0.11, p = 0.57
Wieringa et al. 
(2018)
33 GEE (adjusted for gender, age, 
education, diabetes duration, 
HbA1c, BMI, and number of 
complications)
Mixed; 2+ self- treated symptomatic hypoglycaemic episodes 
led to increased hypoglycaemic worry, but no change 
in general well- being; compared to those reporting 
no episodes, those reporting 2+ self- treated episodes 
showed a rise in HFS- II Worry subscale scores, B = 1.33 
(SE = 0.06), p < 0.001, but no change in WHO- 5 totals, 
B = −0.79 (SE = 0.95), p = 0.30. Experiencing 2+ severe 
hypoglycaemic events led to no change in hypoglycaemic 
worry or general well- being; compared to those reporting 
no events, those reporting 2+ severe events showed no 
change in HFS- II Worry subscale, B = 1.13 (SE = 0.12), 
p = 0.23, or WHO- 5 total scores, B = −1.63 (SE = 1.58), 
p = 0.31. A non- significant interaction between time and 
hypoglycaemic events across all analyses suggested these 
impacts did not change over time
T A B L E  3  (Continued)
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or the Depression subscale of the 22- item W- BQ.29 Unlike 
anxiety, results from these studies showed no relation-
ship between self- treated hypoglycaemia and changes in 
depressive symptoms, regardless of whether assessments 
were made over 1, 3 or 24 months.
Emotional well- being
Four studies examined general emotional well- being. 
Two studies using the World Health Organisation 5- item 
well- being index found that, regardless of whether hypo-
glycaemia was self- treated or severe, emotional well- being 
remained unchanged.33,39 Likewise, a study employing the 
12- item W- BQ found no relationship between self- treated 
events and changes in general emotional well- being over 
a 12- month period.25 Conversely, an RCT using the long- 
form 22- item W- BQ reported a significant drop in emo-
tional well- being among those who experienced four or 
more hypoglycaemic episodes during a 1- month period.29
3.4.4 | Facets in the social domain of QoL
A single study assessed an outcome outside the physical 
and psychological domains of QoL. This small- sample 
study used the Social Support Questionnaire, reporting a 
weak, non- significant correlation between more frequent 
hypoglycaemia symptoms and declines in social support 
over 3 months.31
3.4.5 | Impact of hypoglycaemia on diabetes- 
specific QoL
Studies in this review employed five PROs related to 
diabetes- specific QoL. However, only one study26 utilised 
a global assessment, the Diabetes Quality of Life (DQOL) 
survey, for which participants rated areas commonly im-
pacted by diabetes spanning the physical, psychological 
and social domains. Results showed changes in DQOL to-
tals were not associated with self- treated hypoglycaemic 
episodes over 12 months. Remaining studies (n = 7) ex-
amined the impact of hypoglycaemia on PROs related to 
facets of psychological diabetes- specific QoL.
3.4.6 | Diabetes distress
Using the Diabetes Distress Scale (DDS), a large- sample 
study with a high incidence of hypoglycaemia reported 
greater elevations in diabetes distress among those expe-
riencing self- treated or severe hypoglycaemia over a 3- 
month period.39 However, no impact on DDS totals was 
reported by studies with a small sample31 or lower inci-
dence of hypoglycaemia.30 Similarly, a study assessing di-
abetes distress using the Emotion subscale of the revised 
Illness Perception Questionnaire (IPQ- R) reported no 
change in distress following asymptomatic or self- treated 
symptomatic hypoglycaemia.25
3.4.7 | Diabetes self- efficacy
Diabetes self- efficacy refers to a person's confidence in 
their ability to manage important aspects of diabetes, es-
pecially glycaemic control.40 This outcome was assessed 
by one study31 using the Self- Efficacy for Diabetes Scale 
and another25 using the Control subscale of the IPQ- R, 
both of which reported no change in diabetes self- efficacy 
following self- treated symptomatic hypoglycaemia ex-
perienced over 3 or 24  months, respectively. The latter 
Authors (year)a Reference Analysis Quantified impact on measures of quality of life
Yang et al. (2014) 34 Linear regression (adjusted for 
gender, age, BMI, diabetes 
duration, insulin history, 
HbA1c)
Mixed; 1+ severe hypoglycaemic events led to smaller 
improvements in general health following intervention; 
compared to those reporting no events, those reporting 
1+ severe events showed smaller increases in EQ- 5D 
Visual Analogue Scale scores, B = 6.96, p < 0.001. When 
self- treated symptomatic episodes and severe events were 
combined, this effect was no longer significant; following 
any hypoglycaemic episode, EQ- 5D Visual Analogue Scale 
scores did not change, B = 0.02, p = 0.96
Abbreviations: ANCOVA, Analysis of Covariance; CVR, Cardiovascular Risk; DDS, Diabetes Distress Scale; EQ- 5D, EuroQol 5- Dimension health status 
instrument; GAD, General Anxiety Disorder scale; GEE, Generalised Estimating Equations; HFS- II, Hypoglycaemia Fear Survey version II; IPQ- R, Illness 
Perception Questionnaire Revised; PHQ- 8, Patient Health Questionnaire 8- item; PROMIS, Patient- Reported Outcomes Measurement Information System; 
SEDS, Self- Efficacy for Diabetes Scale; SF- 36, Medical Outcomes Study Short Form 36- item health survey; SSQ, Social Support Questionnaire; W- BQ12 and 
W- BQ22; Well- Being Questionnaire 12- item and 22- item; WHO- 5, World Health Organisation 5- item well- being index.
aStudies which did not report estimates of effect size were omitted from this table.
bTo facilitate comparisons across studies, OR and 95% CI values were converted to β and p, respectively.
T A B L E  3  (Continued)
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study also reported increased self- efficacy among those 
who experienced only asymptomatic hypoglycaemia.25 
Gains in perceived control over diabetes represented a 
small improvement compared to those not experiencing 
hypoglycaemia, and a moderate improvement compared 
to those experiencing self- treated symptomatic episodes. 
Lastly, a study examining the impact of severe hypogly-
caemia found that scores on the Diabetes Self- Efficacy 
Scale dropped among those who experienced at least one 
severe event in 6 months.37
3.4.8 | Impact of hypoglycaemia on 
hypoglycaemia- specific QoL
Fear of hypoglycaemia was the sole hypoglycaemia- 
specific impact uncovered in this review. This outcome 
was assessed by three studies, all using the Hypoglycaemia 
Fear Survey version II (HFS- II). One study27 found those 
who experienced any hypoglycaemia over a 1- month 
period displayed increased HFS- II totals. Similarly, two 
studies reported increased HFS- II Worry subscale scores 
among those experiencing at least one self- treated episode 
over 3 months33 and 24 months.39 Finally, a study assess-
ing the impact of severe events reported a trend towards 
elevated HFS- II Worry subscale scores, although this ef-
fect was non- significant.33 Together, these findings sug-
gest self- treated hypoglycaemia was followed by increased 
fear and worry concerning hypoglycaemia, though im-
pacts for severe events were less clear.
4  |  DISCUSSION
Findings from 20  longitudinal studies included in this 
systematic review demonstrate that, among people with 
type 2 diabetes, hypoglycaemia can have a detrimental im-
pact on key facets within the physical and psychological 
domains of QoL. Specific impacts, however, vary widely 
depending upon frequency and severity of hypoglycae-
mia, as well as choice of QoL measure and the facet(s) and 
domain(s) targeted.
The largest body of evidence concerns health status, 
which broadly captures facets across the physical and 
psychological domains of generic QoL. Multiple studies 
corroborate that perceived health is negatively affected 
by severe hypoglycaemia (i.e. events requiring third- party 
assistance). However, evidence regarding the impact of 
self- treated hypoglycaemia is inconclusive. Studies using 
the EQ- 5D, a brief instrument emphasising physical QoL, 
consistently report that self- treated hypoglycaemia has 
no impact on perceived health. In contrast, studies using 
the more comprehensive SF- 36 provide mixed results; 
hypoglycaemia appears to worsen perceived mental 
health in some studies but not others. Conclusions in this 
review are partially consistent with EQ- 5D research in 
type 1 diabetes5 and EQ- 5D and SF- 36 clinical studies in 
type 2 diabetes,13 all of which report that perceived physi-
cal and mental health is negatively affected by both severe 
and self- treated hypoglycaemia.
Regarding facets in the physical domain of QoL, ap-
proximately 2%– 5% of adults with type 2 diabetes report 
difficulty performing everyday tasks both in and out of 
the workplace each month as a direct consequence of 
hypoglycaemia— impacts similar to those reported by 
adults with type 1 diabetes.23,38 Hypoglycaemia also leads 
to diminished energy, but only among those experiencing 
frequent episodes (four or more per month). Again, this 
impact matches type 1 diabetes research.41 Sleep quality 
may be affected as well, though evidence here is incon-
clusive. Findings from one small- sample study31 reveal 
a non- significant trend towards progressively disturbed 
sleep among those experiencing more frequent symptoms 
of hypoglycaemia. However, significant impacts on sleep 
reported in large- sample cross- sectional studies in type 2 
diabetes,11 as well as laboratory studies in type 1 diabe-
tes,42 lend support to the notion that symptomatic hypo-
glycaemia lowers sleep quality.
Regarding facets in the psychological domain of QoL, 
there is little evidence to suggest hypoglycaemia has long- 
term impacts on general mood. Findings from several 
studies in this review indicate mood positivity and neg-
ativity remain unchanged following self- treated or severe 
hypoglycaemia. Evidence from multiple studies also re-
veals no impact on emotional well- being, as changes are 
comparable for those experiencing severe, self- treated 
and no hypoglycaemia. Nonetheless, the impact of hypo-
glycaemia on emotional well- being may be dose depen-
dent. Findings from one study29 suggest that those with 
frequent episodes (four or more per month) experience 
declines in emotional well- being, matching conclusions 
from research in type 1 diabetes5 and clinical studies in 
type 2 diabetes.13
Measures of mood disorders reveal nuanced impacts. 
According to one study, reductions in anxiety are expe-
rienced by those reporting one, two or three hypogly-
caemic episodes of unspecified severity (but not four or 
more) during a 1- month period.29 However, this counter- 
intuitive finding may be due to habituation to hypoglycae-
mia, or a masking effect caused by the psychotherapeutic 
component of the intervention which produced improve-
ments in nearly all mood- related outcomes in the study. 
Indeed, results from a non- intervention study in this re-
view39 suggest self- treated hypoglycaemia exacerbates 
symptoms of generalised anxiety. In contrast, results from 
several longitudinal studies demonstrate that self- treated 
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hypoglycaemia has no impact on depressive symptoms. 
Type 1 diabetes research reveals a similar pattern, with 
evidence suggesting hypoglycaemia is associated with 
increased symptoms of generalised anxiety43 but not de-
pression.44 Conclusions in this review are somewhat con-
sistent with earlier systematic reviews in type 2 diabetes 
which report increased symptoms of anxiety and depres-
sion in some, but not all, cross- sectional studies.11,12
Evidence concerning impacts outside the physical and 
psychological domains of QoL is sparse. One study in 
this review examined a social outcome, reporting a weak, 
non- significant correlation between more frequent hypo-
glycaemic symptoms and decreased social support.31 This 
analysis was underpowered, however, and given cross- 
sectional evidence in type 1 diabetes research linking 
hypoglycaemia to reduced participation in social activi-
ties,45 large- sample longitudinal confirmatory studies are 
needed.
A considerable body of evidence demonstrates that, 
among adults with type 2 diabetes, hypoglycaemia affects 
diabetes- specific QoL. However, as with generic QoL, 
targeted measures are more informative. A study utilis-
ing a global assessment spanning the physical, psycho-
logical and social domains26 reveals no impact on overall 
diabetes- specific QoL for those experiencing self- treated 
hypoglycaemia. Meanwhile, evidence from a large- sample 
study with a high incidence of hypoglycaemia indicates 
self- treated and severe hypoglycaemia are followed by el-
evations in diabetes distress,39 matching research in type 
1 diabetes.5
Impacts on diabetes self- efficacy are complex. Multiple 
studies suggest confidence in self management of diabetes 
is diminished by severe hypoglycaemia but unaffected by 
self- treated episodes. Intriguingly, one study in this review 
reports that asymptomatic hypoglycaemia leads to modest 
gains in diabetes self- efficacy relative to those without hy-
poglycaemia.25 Taken together, these results suggest that 
experiencing only symptom- free hypoglycaemia may en-
hance diabetes self- efficacy while experiencing severe epi-
sodes may undermine a person's confidence in their ability 
to manage diabetes. Nevertheless, given limited research 
in this area, additional research is needed to confirm these 
impacts in adults with type 1 and type 2 diabetes.
Finally, regarding hypoglycaemia- specific QoL, sev-
eral studies conclude that self- treated hypoglycaemia 
increases fear of hypoglycaemia— an outcome linked to 
other facets of generic QoL, including anxiety and poor 
sleep quality.46 Similar impacts on fear of hypoglycaemia 
are reported in research in type 15 and type 2 diabetes.13 
Conversely, one study in this review reports no change 
in fear of hypoglycaemia following severe events.33 One 
explanation for this lack of effect may be that a focus on 
avoiding hyperglycaemia, coupled with minimisation of 
the consequences of hypoglycaemia, may result in both 
reduced fear and more frequent severe events.47 A second 
explanation is that, unlike self- treated episodes which 
are managed alone, assistance rendered during a severe 
event may increase a person's confidence in their support 
network, reducing uncertainties about future hypogly-
caemia. Indeed, this explanation is supported by studies 
linking perceived lack of social support to greater fear of 
hypoglycaemia.48
4.1 | Limitations and strengths
Findings in this systematic review were limited by the 
characteristics of included studies (e.g. heterogenous 
measures, inadequate statistical information) and by the 
inclusion criteria of the review itself. Searching different 
databases (e.g. JSTOR, PsycExtra) and relaxing the search 
strategy to include qualitative study designs, measures 
other than PROs, and additional terms for specific QoL- 
related outcomes may alter the scope of hypoglycaemic 
impacts detected. This review also has several strengths. 
First and foremost, although studies did not experimen-
tally induce hypoglycaemia, focusing on longitudinal 
studies provides evidence that draws one step closer to 
forming causal inferences about the impact of hypogly-
caemia on changes in QoL. Second, this review had no 
restrictions on language and included studies conducted 
internationally across Europe, North America and Asia, 
the majority of which recruited large and diverse sam-
ples. Finally, in comparison to earlier systematic reviews 
of clinical trials, this review presents findings for a wider 
range of outcomes, detailing impacts for 17 different QoL- 
related measures in the physical, psychological and social 
domains.
4.2 | Recommendations for future  
research
Gaps in understanding identified in this review suggest five 
directions for future investigations. First, more research 
differentiating the effects of symptomatic and asympto-
matic hypoglycaemia is needed. Second, continuous glu-
cose monitoring is important for improving accuracy and 
consistency in measuring hypoglycaemia, and for captur-
ing moment- to- moment fluctuations in blood glucose and 
QoL outcomes, particularly energy and mood.49 Third, 
impaired functioning at work is a commonly reported 
consequence of hypoglycaemia, but statistical evidence 
supporting this effect is needed. Fourth, effect sizes sug-
gest hypoglycaemia has a negative impact on sleep quality 
and social support, but evidence from longitudinal studies 
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with large samples is lacking. Fifth, PROs targeting facets 
across all domains of QoL, particularly the social domain, 
and hypoglycaemia- specific QoL measures are currently 
underutilised.
5  |  CONCLUSIONS
Evidence from longitudinal studies demonstrates hypogly-
caemia is relatively common among adults with type 2 di-
abetes, and its impacts on QoL parallel those experienced 
by adults with type 1 diabetes. Severe hypoglycaemia in 
type 2 diabetes is associated with reduced confidence in 
diabetes self- management and lower ratings of perceived 
health. Self- treated symptomatic hypoglycaemia is fol-
lowed by reductions in physical QoL, including impaired 
functioning at work and in daily life. Self- treated hypo-
glycaemia is also associated with declines in psychological 
QoL, including elevated symptoms of generalised anxiety, 
diabetes distress and fear of hypoglycaemia. Frequent 
hypoglycaemia is followed by diminished energy and 
emotional well- being. Nevertheless, available evidence is 
insufficient to establish whether hypoglycaemia impacts 
sleep quality, depressive symptoms, general mood, social 
support or overall diabetes- specific QoL. Further longitu-
dinal research is needed targeting more varied facets of 
QoL, particularly in the social domain. Research delineat-
ing impacts on individual facets of QoL based on hypo-
glycaemic severity will also be important for improving 
existing measures,50 developing new hypoglycaemia- 
specific measures which better capture the breadth of QoL 
and designing targeted interventions aimed at improving 
QoL on an outcome- by- outcome basis.
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